Utrecht,
10
November
2016
|
18:29
Europe/Amsterdam

Researchers observe receptor for cell division in action

Important activation step to cancer revealed

Summary

Researchers at Utrecht University have revealed structural changes in a receptor that plays a key role in many types of cancer. The changes occur before and during receptor activation. These findings provide novel clues to develop medication to target the disease. For the first time, a receptor of this size could be studied in its natural environment. The researchers are publishing their results in the journal Cell today.

The researchers studied a receptor that can be activated by the epidermal growth factor (EGF), a hormone that stimulates cell division. Genetic defects can lead to too many of these receptors in the cell membrane. This overstimulates cell division, leading to cancer.

Natural environment

To study the EGF receptor, the Utrecht scientists used a new approach in the field of NMR spectroscopy. This enabled them to observe structural changes of the receptor in its native environment – the cell membrane. “Previously, only parts of the receptor had been analysed and then only outside its cellular environment”, says Marc Baldus, professor of NMR spectroscopy at Utrecht University and one of the publication's authors. “We can now observe how the receptor behaves in a cellular setting. This technique has great promise and can also be used to study other proteins associated with cancer or other diseases, such as Alzheimer's or Parkinson's”.

Prof.  Marc Baldus
We can now observe how the receptor behaves in a cellular setting. This technique has great promise and can also be used to study other proteins associated with cancer or other diseases, such as Alzheimer's or Parkinson's
Prof. Marc Baldus

Dancing around

Using the method, the researchers discovered that the receptor continually changes shape in the absence of the EGF hormone. “We believe that the receptor in its ligand free state is continually switching from a ‘closed’ to an ‘open’ position and vice-versa”, says Paul van Bergen en Henegouwen, cellular biologist at Utrecht University and one of the authors of the article. “It so to speak dances around and continuously bows for its audience”.

New cancer drugs

In his lab, Van Bergen en Henegouwen develops antibody fragments, known as nanobodies, that can specifically bind to EGF receptors. These nanobodies can therefor be used to label tumour cells, which enables the specific destruction of such cells. “Since we now know more about the structure and dynamics of the EGF receptor, we can start designing nanobodies that specifically bind to the open, active form of the receptor. This can ultimately lead to new cancer drugs.”

Dr. Paul van Bergen en Henegouwen
Since we now know more about the structure and dynamics of the EGF receptor, we can start designing nanobodies that specifically bind to the open, active form of the receptor. This can ultimately lead to new cancer drugs.
Dr. Paul van Bergen en Henegouwen

Figures

Representation of the cell-membrane (gray) with the dancing unbound EGF-receptors on the left (purple) and the EGF hormone (orange) bound receptors on the right (green). After binding of the hormone, the receptor stops dancing and finds a second bound receptor to form a dimer of receptors. You can download the figures below both in high and low resolution.

Publication

'EGFR Dynamics Change during Activation in Native Membranes as Revealed by NMR'

Cell, 10 november 2016, doi.org/10.1016/j.cell.2016.10.038

Mohammed Kaplan,Siddarth Narasimhan, Cecilia de Heus, Deni Mance,Sander van Doorn, Klaartje Houben, Dusan Popov-Celeketic, Reinier Damman, Eugene A. Katrukha, Purvi Jain, Willie J.C. Geerts, Albert J.R. Heck, Gert Folkers, Lukas C. Kapitein, Simone Lemeer, Paul M.P. van Bergen en Henegouwen and Marc Baldus

This research is conducted within Utrecht University's research theme Life Sciences and was supported by the Netherlands Organization for Scientific Research (NWO).

 

Comments (0)
Thank you for your message. It will be posted after approval.
Share this release

Latest news